News

Published on 7 Sep 2022 on Benzinga via Yahoo Finance

Glaukos Shares Pop After Positive Data From Ocular Pressure Candidate


Article preview image

Glaukos Corporation (NASDAQ: GKOS) announced positive topline data for both Phase 3 trials of iDose TR. It achieved its pre-specified primary efficacy endpoints through 3 months and demonstrated excellent tolerability and a favorable safety profile through 12 months.The fast- and slow-release iDose TR arms achieved the primary efficacy endpoint of non-inferiority to the active comparator arm (topical timolol ophthalmic solution).Related: Glaukos Inks Licensing Pact For Rare Eye Disorder Treatment.For the GC-010 trial, the intraocular pressure (IOP) reductions from baseline were 6.6-8.5 mmHg in the slow-release iDose TR arm versus 6.6-7.7 mmHg in the timolol control arm.For the GC-012 trial, IOP reductions were 6.7-8.4 mmHg in the slow-release iDose TR arm versus 6.8-7.2 mmHg in the timolol control arm.93% of slow-release iDose TR subjects remained well-controlled on the same or fewer IOP-lowering topical medications at 12 months compared to screening after a single administration of iDose TR, versus 67% of timolol control subjects.Additionally, 81% of slow-release iDose TR subjects were completely free of IOP-lowering topical medications.iDose TR demonstrated a favorable safety profile.Glaukos plans to move forward with its plans for marketing application submission to the FDA for the slow-release iDose TR model, with an expected FDA review and decision completed by the end of 2023.Price Action: GKOS shares are up 16.80% at $56.16 on the last check Wednesday.

See more from Benzinga

NYSE.GKOS price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
3 Reasons to Retain Glaukos (GKOS) Stock in Your Portfolio

Glaukos Corporation GKOS is well-poised for growth in the coming quarters, courtesy of its favora...

Zacks via Yahoo Finance 28 Dec 2022

Glaukos (GKOS) Up 0.8% Since Last Earnings Report: Can It Continue?

A month has gone by since the last earnings report for Glaukos (GKOS). Shares have added about 0....

Zacks via Yahoo Finance 2 Dec 2022

Despite currently being unprofitable, Glaukos (NYSE:GKOS) has delivered a 79% return to shareholders...

Glaukos Corporation (NYSE:GKOS) shareholders have seen the share price descend 16% over the month...

Simply Wall St. via Yahoo Finance 26 Nov 2022

Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio

Glaukos Corporation GKOS is well-poised for growth, backed by favorable clinical trial results an...

Zacks via Yahoo Finance 23 Nov 2022

Glaukos (GKOS) Beats on Q3 Earnings, Tightens Sales View

Glaukos Corporation GKOS reported an adjusted loss per share of 45 cents for the third quarter of...

Zacks via Yahoo Finance 3 Nov 2022

Glaukos (GKOS) Reports Q3 Loss, Tops Revenue Estimates

Glaukos (GKOS) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estim...

Zacks via Yahoo Finance 2 Nov 2022

The Zacks Analyst Blog Highlights Nevro, Masimo, Abiomed and Glaukos

For Immediate Release Chicago, IL – October 28, 2022 – Zacks.com announces the list of stocks fea...

Zacks via Yahoo Finance 28 Oct 2022

Glaukos (GKOS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Wall Street expects a year-over-year decline in earnings on lower revenues when Glaukos (GKOS) re...

Zacks via Yahoo Finance 26 Oct 2022

Why IMARA Jumped Around 75%; Here Are 54 Biggest Movers From Yesterday By Benzinga

Why IMARA Jumped Around 75%; Here Are 54 Biggest Movers From Yesterday

Investing.com 8 Sep 2022

Glaukos (GKOS) Up on Positive Glaucoma Study Data on iDose TR

Glaukos Corporation GKOS announced positive top-line data from two pivotal studies evaluating its...

Zacks via Yahoo Finance 8 Sep 2022